Company news
Noxopharm Ltd. (ASX:NOX) news
Noxopharm Ltd. news releases on 6ix. Latest, Feb 27, 2024: Appendix 4D and Half Year 2024 Financial Report
Press releases — page 2
Appendix 4D and Half Year 2024 Financial Report
February 26, 2024
December 2023 Quarterly Activities Report and Appendix 4C
January 22, 2024
Noxopharm Enhances Cash Position via R&D Rebate
November 15, 2023
Noxopharm 2023 AGM Corporate Presentation
November 15, 2023
mRNA Vaccine Enhancer Shows Inflammation Reduction
October 17, 2023
September 2023 Activities Report and Appendix 4C
October 12, 2023
Response to ASX Query
October 8, 2023
US FDA grants Orphan Drug Designation for CRO-67
October 3, 2023
Trading Halt
October 3, 2023
Pause in Trading
October 3, 2023
Latest CRO-67 data shows success in reducing cancer growth
September 27, 2023
Appendix 4E and Audited Financial Statements
August 31, 2023
June 2023 Activities Report and Appendix 4C
July 13, 2023
IONIC Trial Abstract Published at ASCO
May 25, 2023
Study results show new Sofra drug reduces inflammation
May 18, 2023
March 2023 Quarterly Activities Report and Appendix 4C
April 23, 2023
Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
April 5, 2023
Noxopharm Announces Novel mRNA Vaccine Enhancer
March 27, 2023
Appendix 4D and Half Year 2023 Financial Report
February 24, 2023
December 2022 Quarterly Activities Report and Appendix 4C
January 26, 2023
DARRT-2 Trial Efficacy Phase to Commence
January 16, 2023
NOX Pipeline Boosted by $1.5M Grant to Hudson Institute
December 15, 2022
September 2022 Quarterly Activities Report and Appendix 4C
October 20, 2022
Novel Dual-cell Therapy Results in Pancreatic Cancer
September 13, 2022
Response to ASX Price Query
September 1, 2022
June 2022 Quarterly Activities Report and Appendix 4C
July 26, 2022
March 2022 Quarterly Activities Report and Appendix 4C
April 27, 2022
FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment
March 29, 2022
Orphan Drug Designation Granted to Noxopharm by US FDA
March 21, 2022
First Patient Treated in CEP-2 Sarcoma Trial
February 27, 2022
Appendix 4D and Half Year 2022 Financial Report
February 21, 2022
December 2021 Quarterly Activities Report and Appendix 4C
January 26, 2022
Noxopharm Receives A$5.865M R & D Tax Rebate
January 6, 2022
Noxopharm Announces Leadership Transition
January 4, 2022
Noxopharm DARRT-2 Cancer Trial Update
December 13, 2021
Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research
December 1, 2021
Licencing Deal Expands Noxopharm Drug Opportunities
November 16, 2021
Retraction of Grant Announcement
November 16, 2021
Noxopharm Awarded A$8.8M Aust Govt Grant for Sarcoma Trial
November 14, 2021
Noxopharm Announces DARRT-2 Clinical Trial in U.S.
November 9, 2021
Veyonda and Opdivo IONIC Study First Patient Dosed
October 25, 2021
Patent Granted for Veyonda and Low Dose Chemotherapy
October 25, 2021
September 2021 Quarterly Activities Report and Appendix 4C
October 13, 2021
Veyonda Achieves Important U.S. Patent Claims
September 27, 2021
Noxopharm : Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19
August 26, 2021
Noxopharm : Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients
August 25, 2021
Pre-clinical Data Supports a Role for Veyonda in COVID-19
August 23, 2021
NOXCOVID Program to Expand After Positive Phase 1 Results
August 22, 2021
Noxopharm : Pre-clinical Study Confirms Survival Advantage of Combination LuPSMA Therapy in Prostate Cancer
August 12, 2021
NOX and US Govt Peak Cancer Agency Announce Collaboration
August 8, 2021